文献速递泌尿男性生殖肿瘤支持与姑息治疗

硒化学预防非浸润性尿路上皮癌复发的III期随机研究:硒与膀胱癌试验

Phase III randomised chemoprevention study with selenium on the recurrence of non-invasive urothelial carcinoma. The SELEnium and BLAdder cancer Trial.
PubMed 文献 · Eur J Cancer · 2016-10-29

SELEBLAT是一项在比利时14家医院开展的III期安慰剂对照双盲随机试验,旨在评估口服硒酵母200 μg每日一次持续三年对非浸润性尿路上皮癌复发的影响。共随机分配硒组151例和安慰剂组141例,意向治疗分析显示硒组复发43例(28%;95%CI 0.21-0.35),安慰剂组45例(32%;95%CI 0.24-0.40),HR为0.85(95%CI 0.56-1.29;p=0.44)。结论为补硒不能降低膀胱癌患者的复发概率。

要点

  • 硒酵母200 μg每日一次持续三年未降低非浸润性尿路上皮癌复发风险(HR 0.85;95%CI 0.56-1.29;p=0.44)。
  • 符合方案分析中硒组复发42例,安慰剂组39例(28%;95%CI 0.20-0.35),HR为0.96(95%CI 0.62-1.48;p=0.93)。
  • 补硒不能降低膀胱癌患者的复发概率。

核心结论

  • 补硒不能降低膀胱癌患者的复发概率。

研究设计与样本

  • SELEBLAT为学术性III期安慰剂对照双盲随机临床试验,在比利时14家医院开展,旨在确定硒对非浸润性尿路上皮癌复发的影响。
  • 患者经计算机程序随机分配至口服硒酵母200 μg每日一次或安慰剂组,持续三年,并接受标准治疗。
  • 研究期间所有研究人员和参与者对治疗分配设盲;所有随机患者均纳入意向治疗(ITT)和安全性分析;符合方案分析(PPA)纳入开始日期后三个月时仍在研究中的所有患者。
  • 2009年9月18日至2013年4月18日期间,硒组和安慰剂组分别随机分配151例和141例患者;随访至2015年12月31日。

主要发现

  • ITT分析中硒组和安慰剂组分别发生43例(28%;95%CI 0.21-0.35)和45例(32%;95%CI 0.24-0.40)复发,HR为0.85(95%CI 0.56-1.29;p=0.44)。
  • PPA中硒组和安慰剂组分别发生42例和39例(28%;95%CI 0.20-0.35)复发,HR为0.96(95%CI 0.62-1.48;p=0.93)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: In Belgium, bladder cancer (BC) is the fifth most common cancer in men. The per-patient lifetime cost is high. Previous epidemiological studies have consistently reported that selenium concentrations were inversely associated with the risk of BC. We therefore hypothesised that selenium may be suitable for chemoprevention of recurrence of BC. METHOD: The Selenium and Bladder Cancer Trial (SELEBLAT) was an academic phase III placebo-controlled, double-blind, randomised clinical trial designed to determine the effect of selenium on recurrence of non-invasive urothelial carcinoma conducted in 14 Belgian hospitals. Patients were randomly assigned by a computer program to oral selenium yeast 200 μg once a day or placebo for three years, in addition to standard care. All study personnel and participants were blinded to treatment assignment for the duration of the study. All randomised patients were included in the intention to treat (ITT) and safety analyses. Per protocol analyses (PPAs) included all patients in the study three months after start date. RESULTS: Between September 18, 2009 and April 18, 2013, 151 and 141 patients were randomised in the selenium and placebo group. Patients were followed until December 31, 2015. The ITT analysis resulted in 43 (28%; 95% CI, 0.21-0.35) and 45 (32%; 95% CI, 0.24-0.40) recurrences in the selenium and placebo group. The hazard ratio (HR) was 0.85 (95% CI, 0.56-1.29; p = 0.44) while the HR for the PPA resulted in 42 and 39 (28%; 95% CI, 0.20-0.35) recurrences in the selenium and placebo group (HR = 0.96 [95% CI, 0.62-1.48]; p = 0.93). CONCLUSION: Selenium supplementation does not lower the probability of recurrence in BC patients.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Goossens ME, Zeegers MP, van Poppel H, et al. Phase III randomised chemoprevention study with selenium on the recurrence of non-invasive urothelial carcinoma. The SELEnium and BLAdder cancer Trial. Eur J Cancer. 2016. PMID: 27814472. doi:10.1016/j.ejca.2016.09.021

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。